Animal viruses are broadly categorized structurally by the presence or absence of an envelope composed of a lipid-bilayer membrane 1 , attributes that profoundly affect stability, transmission and immune recognition. Among those lacking an envelope, the Picornaviridae are a large and diverse family of positive-strand RNA viruses that includes hepatitis A virus (HAV), an ancient human pathogen that remains a common cause of enterically transmitted hepatitis [2] [3] [4] . HAV infects in a stealth-like manner and replicates efficiently in the liver 5 . Virus-specific antibodies appear only after 3-4 weeks of infection, and typically herald its resolution 3, 4 . Although unexplained mechanistically, both anti-HAV antibody and inactivated whole-virus vaccines prevent disease when administered as late as 2 weeks after exposure 6 , when virus replication is well established in the liver 5 . Here we show that HAV released from cells is cloaked in host-derived membranes, thereby protecting the virion from antibody-mediated neutralization. These enveloped viruses ('eHAV') resemble exosomes 7 , small vesicles that are increasingly recognized to be important in intercellular communications. They are fully infectious, sensitive to extraction with chloroform, and circulate in the blood of infected humans. Their biogenesis is dependent on host proteins associated with endosomal-sorting complexes required for transport (ESCRT) 8 , namely VPS4B and ALIX. Whereas the hijacking of membranes by HAV facilitates escape from neutralizing antibodies and probably promotes virus spread within the liver, anti-capsid antibodies restrict replication after infection with eHAV, suggesting a possible explanation for prophylaxis after exposure. Membrane hijacking by HAV blurs the classic distinction between 'enveloped' and 'non-enveloped' viruses and has broad implications for mechanisms of viral egress from infected cells as well as host immune responses.
Supernatant fluids of hepatoma cell cultures infected with lowpassage, non-cytopathic HAV 9 (Fig. 1A ) contain two populations of virus particles that are resolved in isopycnic iodixanol gradients ( Fig. 1B) . One bands at a low density consistent with membrane association (1.06-1.10 g cm 23 , fractions 8-12) and is not detected in a capsid antigen enzyme-linked immunosorbent assay (ELISA) (Fig. 1C, left) , whereas the other bands at the density expected for picornaviruses (1.22-1.28 g cm 23 , fractions [18] [19] [20] [21] [22] and is readily detected by ELISA. Electron microscopy of the light fractions revealed numerous virus-like particles enclosed in membranes (see a-d in Fig. 1D , and Supplementary Fig. 1a ) with morphology indistinguishable from ,27-nm HAV particles in dense fractions (see e in Fig. 1D ). These membrane-bound structures ranged from 50 to 110 nm in diameter, a size similar to that of exosomes 7 , and contained one to four virus-like particles ( Supplementary Fig. 1b ). Consistent with this, viral RNA banded in gradients with capsid protein (VP2) and the exosomeassociated protein flotillin-1 ( Supplementary Fig. 1c ).
A modified plaque assay (infrared fluorescence immunofocus assay; IR-FIFA) 10 revealed the membrane-wrapped particles to be infectious ( Fig. 1E ) with a specific infectivity equivalent to that of virions ( Fig. 1F ). Extraction with chloroform, a classic method for distinguishing enveloped from non-enveloped viruses, had no effect on standard virions but resulted in a 2log 10 decrease in infectious virus in the light fraction ( Fig. 1E and Supplementary Fig. 2a ). We call these membranewrapped HAV particles 'enveloped HAV' (eHAV). Capsid antigen could be detected in the eHAV fraction after treatment with a nonionic detergent (1% Igepal CA-630; NP-40) ( Fig. 1C, right) . This shifted the viral particles to an intermediate density in iodixanol gradients (1.15-1.17 g cm 23 ) but did not destroy infectivity ( Supplementary Fig. 2b , c). A potent, neutralizing, monoclonal antibody (mAb), K24F2 (ref. 11), failed to neutralize eHAV ( Fig. 1G ), providing further evidence for complete envelopment of the capsid.
In 12 experiments, eHAV represented 79 6 13% (mean 6 s.d.) of virus in medium from infected cell cultures. eHAV was released from multiple cell types and was also observed with high-passage cytopathic virus ( Supplementary Fig. 3a-e ). Gradient-purified eHAV contained mostly mature VP2 (Fig. 1H , lane 3, and Supplementary Fig. 2d ), indicating that enveloped virions had undergone maturation cleavage of VP0 to VP4 1 VP2. However, whereas non-enveloped virions contained fully processed VP1, eHAV contained primarily unprocessed VP1pX (Fig. 1H ; compare lanes 3 and 4). pX is an unusual 8-kDa carboxy-terminal extension on VP1 that is unique to HAV among picornaviruses ( Fig. 1A ). It functions in virion assembly and is processed from VP1 by an unidentified host protease late in the viral lifecycle 12, 13 . pX was protected from proteinase K in eHAV particles, but was rendered susceptible to digestion after treatment with NP-40 ( Supplementary Fig. 2e ). Thus, pX is fully enclosed in membranes. We conclude that most HAV is released enveloped in host membranes, a process we term 'membrane hijacking'.
Infectious virus circulating in the blood of infected humans and chimpanzees (Pan troglodytes) possesses the buoyant density of eHAV ( Fig. 2a and Supplementary Fig. 4a-e ), confirming the relevance of these observations to HAV pathogenesis. However, virus in faeces is non-enveloped ( Fig. 2b and Supplementary Fig. 4c ). Because most faecal virus is produced in the liver 14, 15 , the membrane may be stripped from eHAV during passage through the biliary tract to the gut. However, suspending eHAV in bile minimally altered its buoyant density ( Supplementary Fig. 5a ).
It has been suggested 16 that poliovirus, a distantly related picornavirus, could be released from cells wrapped in a single membrane if entrapped in an autophagosome that fuses with the plasma membrane. However, RNA-mediated interference knockdown of beclin-1, which mediates autophagosome formation, did not inhibit eHAV release ( Supplementary Fig. 6a, b ). In contrast, knockdown of VPS4B or ALIX, which are ESCRT-III-associated proteins that facilitate the budding of many enveloped viruses [17] [18] [19] [20] , inhibited the release of eHAV from cells ( Fig. 3a-c and Supplementary Figs 6c and 7a) but not viral RNA replication ( Fig. 3d ), intracellular assembly of capsids or encapsidation of viral RNA ( Supplementary Fig. 7a -c). ESCRT complexes act sequentially to sort and load cargo into multivesicular bodies (MVBs) 8 . VPS4B is an ATPase that provides energy for the dissolution of ESCRT-III complexes at membrane fission, whereas ALIX contributes to exosome biogenesis and also facilitates lentivirus budding 8, 19, 21 . Knockdown of VPS4B and ALIX inhibited the release of both enveloped and non-enveloped HAV ( Fig. 3c ), suggesting these share a common egress pathway and that non-enveloped virus in extracellular fluids might be derived from eHAV. Knockdown of HRS and TSG101, which are ESCRT-0 and ESCRT-I proteins involved early in cargo recruitment, did not inhibit eHAV release (Fig. 3b , c). Thus, eHAV release is dependent on ESCRT-associated proteins but not on the entire ESCRT machinery, in a similar manner to the budding of some enveloped viruses 8, 18 . Although an interaction of ALIX with the ESCRT-III protein CHMP4B facilitates the budding of human immunodeficiency virus 22 , CHMP4A, CHMP4B or CHMP4C knockdown minimally decreased eHAV release (Supplementary Fig. 8 ).
Structural proteins of enveloped viruses interact with ESCRT-related proteins by means of Pro-rich late ('L') domain motifs: PPXY, P(S/T)AP or (L)YPX 1/3 L (refs 8, 17). Only two domains in the 2,227-residue-long HAV polyprotein conform to these motifs: conserved, tandem YPX 3 L motifs separated by 28 residues in the VP2 capsid protein (Fig. 3e ). YPX 1/3 L motifs mediate interactions with ALIX (ref. 19) , and their presence in VP2 is consistent with a requirement for ALIX. Disrupting either Supplementary Fig. 4) . The low buoyant density of circulating virus was not due to a passive effect of serum, because the buoyant density of non-enveloped virions was not altered by suspension in 90% serum (data not shown).
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YPX 3 L motif by substituting Ala for Tyr ( Fig. 3e ) severely decreased virus release but did not impair viral RNA replication (Fig. 3f, g) . Intracellular capsid antigen was similarly decreased, suggesting that the mutations impede capsid assembly, but the antigen was detected in cells transfected with Y-A(II) RNA in which the second YPX 3 L motif had been ablated (Fig. 3h ). Limited capsid assembly was confirmed by K24F2 precipitation of RNase-protected viral RNA from detergenttreated cell lysates (Fig. 3i ). Consistent with a role for ALIX in eHAV biogenesis, anti-ALIX antibody precipitated encapsidated (RNaseprotected) viral RNA from lysates of cells transfected with wild-type, but not Y-A(II), RNA (Fig. 3i ). Furthermore, ALIX banded at the same density as eHAV in iodixanol gradients ( Supplementary Fig. 7d ). Although details remain to be worked out, these data suggest that HAV co-opts ALIX to facilitate its envelopment in host membranes. Where this occurs is uncertain, but HAV particles have been observed within cytoplasmic vesicles in infected liver 14, 23 .
The cloaking of its capsid by membranes allows eHAV to evade neutralizing antibodies ( Fig. 1G and Supplementary Fig. 9a ) and explains how infectious virus co-exists with anti-HAV in serum 15 . However, antibodies protect against hepatitis A when passively transferred after HAV replication has been well established in the liver 5,6 . We therefore reasoned that eHAV might be neutralized after binding to or entering hepatocytes. Consistent with this, eHAV was neutralized when cells were exposed to antibody either immediately before inoculation with virus or up to 6 h afterwards (Fig. 4a, b ). IgG and IgA anticapsid mAbs neutralized eHAV when added to cultures after removal of the inoculum, but an IgM mAb, H14C42 (ref. 11), failed to do so despite potent neutralizing activity against non-enveloped HAV (Supplementary Fig. 9b ). Taken together, these results show capsid is the target for neutralization and that eHAV membranes must rupture before neutralization, but not before eHAV is internalized and inaccessible to H14C42 in the medium. This suggests that eHAV may be neutralized after endocytosis. Chloroquine efficiently blocked infection by eHAV (but not by non-enveloped HAV) ( Fig. 4c) , indicating that endosomal acidification is important for eHAV entry, whereas an antibody against the HAV receptor, TIM-1 (HAVCR-1) 24 , inhibited both (Fig. 4d ). We found eHAV membranes to be stable at pH 5.0 ( Supplementary Fig. 5b ), but they could nonetheless be degraded in late endosomes and lysosomes 25 . If so, this would render the capsid accessible to TIM-1, which undergoes constitutive endocytosis and trafficking to late endosomes and lysosomes 26 , as well as to anti-HAV. Many details of eHAV entry and neutralization remain to be explained. However, TRIM-21 (tripartite motif-containing 21), which is implicated in intracellular neutralization of other viruses 27 , seems to have no function in neutralization of eHAV ( Supplementary  Fig. 9c ). a, Immunoblots of HRS, TSG101, VPS4B and ALIX in HAV-infected cells 72 h after transfection with the indicated gene-specific targeting (T) or nontargeting (NT) control siRNAs. Asterisks, non-specific bands. qRT-PCR assays confirmed knockdown of TSG101 and VPS4B ( Supplementary Fig. 6c ). b, Viral RNA detected in culture fluids 48-72 h after siRNA transfection. c, Relative yield and buoyant density of virus released from siRNA transfected cells (as in a) determined in iodixanol gradients. RNA associated with eHAV particles (fractions 8-12) was decreased by 85% and 87% by depletion of VPS4B and ALIX, respectively. d, One-step growth of eHAV. Huh-7.5 cells were transfected with the indicated siRNAs for 3 days, then infected with gradientpurified eHAV at a multiplicity of infection of 20. Cell-associated HAV RNA was assayed by qRT-PCR. Knockdown efficiency was confirmed at the end of the experiment (not shown). e, Tandem YPX 3 L ALIX-interacting motifs (red) in VP2. Below are the motif sequences in wild-type (WT, HM175/18f) and mutant viral RNAs. f, Viral RNA released into culture fluids 24-48 h after electroporation of Huh-7.5 cells with wild-type and mutant viral RNAs. D3D is a replication-incompetent subgenomic replicon RNA with a frameshift mutation in 3D pol . g, Intracellular HAV RNA after electroporation of cells with WT and VP2 mutant RNAs. h, Confocal microscopy showing K24F2 detection of capsid antigen in cells electroporated 48 h previously with WT or mutant RNAs. K24F2 recognizes a conformation-dependent assembled neutralization epitope in the viral capsid 11 . i, Anti-capsid (K24F2) and anti-ALIX (Bethyl) antibody-mediated immunoprecipitation of encapsidated, RNase-resistant viral RNA in detergent-treated lysates of cells electroporated with wild-type or mutant HAV RNAs. RT-PCR data are means 6 s.e.m. for two or three replicate assays; all results are representative of two or three independent experiments.
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Our findings show how a 'non-enveloped' picornavirus promotes its egress in the absence of cell lysis, and reveal a previously unrecognized strategy by which a virus cloaks itself in host membranes to evade neutralizing antibodies. The host membrane enveloping eHAV is likely to facilitate its spread within the liver. Antibodies restrict the replication of eHAV when added to cultures several hours after infection, but further studies will be needed to determine how this happens and whether this can explain why immune globulin and vaccines protect against hepatitis when administered long after exposure, when virus is already circulating in blood 5 . Our results suggest that categorizing viruses into those that are enveloped and those that are not, long a tradition in virology 1 , is overly simplistic, and that efforts should be made to identify other examples of membrane hijacking by 'nonenveloped' viruses.
METHODS SUMMARY
Non-cytopathic, cell-culture-adapted HM175/p16 HAV 9 was propagated in Huh-7.5 cells. Reverse molecular genetics studies were performed with pHM175/18f, a molecular clone of a related cytopathic variant 28 . Buoyant density was assessed in 8-40% iodixanol (Opti-Prep) gradients centrifuged at 141,000g for 48 h at 4 uC. Viral RNA was measured by quantitative PCR with reverse transcription (qRT-PCR) with primers targeting the 59 untranslated region. Infectivity was quantified by IR-FIFA 10 . For RNA-mediated interference studies, cells were transfected with SmartPool short interfering RNAs (siRNAs) (Dharmacon) and samples were collected 48-72 h later for viral RNA quantification. To analyse VP2-ALIX interactions, cell lysates were prepared 48 h after electroporation of mutant and wildtype viral RNAs, treated with RNase and immunoprecipitated. RNA extracted from immunoprecipitates was assayed by HAV-specific qRT-PCR. For intracellular neutralization, cells were incubated with eHAV for 1 h at 37 uC, then washed extensively. Antibodies were added at intervals, and intracellular and extracellular HAV RNA was quantified at 48-72 h. For standard neutralization assays, virus was incubated with antibodies for 1 h at 37 uC, then inoculated onto cells for IR-FIFA 10 . blocks eHAV entry but not HAV entry. Cells were treated for 30 min before inoculation with virus, and were harvested at 48 h to assay intracellular HAV RNA. d, Anti-TIM-1 mAb 190-4 blocks entry of both eHAV and HAV. GL37 cells were incubated with 190-4 (10-100 mg ml 21 ) or control IgG (100 mg ml 21 ) for 1 h at 37 uC, then inoculated with virus for 1 h. Intracellular HAV RNA was assayed at 72 h. RT-PCR data are means 6 s.e.m. for two or three replicate assays; all results are representative of two or three independent experiments.
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